After decades of hype and setbacks, scientists have made impressive progress into tricking stem cells into repairing organs.

European shares extended gains on Friday, supported by healthcare stocks, and were on track to end the week in positive ...

The use of stereotactic body radiotherapy (SBRT) as salvage therapy after radical prostatectomy was well tolerated, with no ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

President Donald Trump's executive order on drug pricing may threaten Roche's planned $50 billion investment in the U.S. By ...

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

Risk for the autoimmune hair disorder was reduced by nearly 75% in patients on these treatments for psoriasis, finds a ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid ...

Global pharmaceutical shares are slumping Monday after President Donald Trump said he is looking to slash the price of ...

Shares of global pharma stocks slumped on Monday after President Trump vowed to cut drug prices for Americans by as much as 80%.